Why Vir Biotechnology Stock Is Plunging Today?
Portfolio Pulse from Vandana Singh
Vir Biotechnology Inc's shares are falling after the company released data from the Phase 2 PENINSULA trial evaluating VIR-2482 for preventing symptomatic influenza A illness. The trial did not meet primary or secondary efficacy endpoints. However, VIR-2482 was generally well tolerated, and no safety signals were identified. The company's shares are down 41.6% at $13.68.
July 20, 2023 | 1:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Vir Biotechnology's stock is plunging due to the failure of the Phase 2 trial of VIR-2482 to meet its primary or secondary efficacy endpoints.
The failure of a clinical trial is a significant event for a biotech company, as it can indicate that a potential product may not be as effective as hoped. This can lead to a decrease in investor confidence and a drop in the company's stock price, as seen with Vir Biotechnology.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100